ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP30-26 Commercial Pharmacy Benefit Exclusion for Avlayah™ and Qivigy™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 13, 2026
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 4231 - 4240 လၢ 4294 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP38-26 MHCP Pharmacy Benefit Exclusion for Avopef™, Epioxa™ HD/Epioxa, Fesilty™, Midazolam, Photrexa®, and Wainua®
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 27, 2026
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP37-26 Commercial Pharmacy Benefit Exclusion for Epioxa™ HD/Epioxa, Fensolvi®, Fesilty™, Midazolam, Photrexa®, Wainua®, Zemaira®, and Zoladex®
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 27, 2026
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP36-26 Commercial Pharmacy Benefit Exclusion for Select Medications
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 27, 2026
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP35-26 Intensive Residential Treatment Services (IRTS) Prior Authorization (PA) Requirements
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 27, 2026
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP34-26 Billing Changes for Opioid Treatment Programs for Minnesota Health Care Programs
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 27, 2026
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Compounded Medications - Commercial
Formulary Exception, Coverage Exception
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 01, 2026